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Abstract
Background: Inherited mutations in the BRCA2 gene greatly increase the risk of developing breast cancer.
Consistent with an important role for BRCA2 in error-free DNA repair, complex genomic changes are frequently
observed in tumors derived from BRCA2 mutation carriers. Here, we explore the impact of DNA copy-number
changes in BRCA2 tumors with respect to phenotype and clinical staging of the disease.
Methods: Breast tumors (n = 33) derived from BRCA2 999del5 mutation carriers were examined in terms of copy-
number changes with high-resolution aCGH (array comparative genomic hybridization) containing 385 thousand
probes (about one for each 7 kbp) and expression of phenotypic markers on TMAs (tissue microarrays). The data
were examined with respect to clinical parameters including TNM staging, histologic grade, S phase, and ploidy.
Results: Tumors from BRCA2 carriers of luminal and basal/triple-negative phenotypes (TNPs) differ with respect to
patterns of DNA copy-number changes. The basal/TNP subtype was characterized by lack of pRb (RB1) coupled
with high/intense expression of p16 (CDKN2A) gene products. We found increased proportions of Ki-67-positive
cells to be significantly associated with loss of the wild-type (wt) BRCA2 allele in luminal types, whereas BRCA2wt
loss was less frequent in BRCA2 tumors displaying basal/TNP phenotypes. Furthermore, we show that deletions at
13q13.1, involving the BRCA2wt allele, represents a part of a larger network of co-occurring genetic changes,
including deletions at 6q22.32-q22.33, 11q14.2-q24.1, and gains at 17q24.1. Importantly, copy-number changes at
these BRCA2-linked networking regions coincide with those associated with advanced progression, involving the
capacity to metastasize to the nodes or more-distant sites at diagnosis.
Conclusions: The results presented here demonstrate divergent paths of tumor evolution in BRCA2 carriers and
that deletion of the wild-type BRCA2 allele, together with co-occurring changes at 6 q, 11 q, and 17 q, are
important events in progression toward advanced disease.
Introduction
Germline mutations in one allele of the BRCA2 tumor-
suppressor gene confer greatly increased risk of develop-
ing breast cancer [1]. The BRCA2 gene is known to be
involved in error-free DNA repair of double-strand
breaks (DSBs) through homologous recombination (HR)
[2]. Defects in this mechanism lead to repair of DSBs by
error-prone nonhomologous end joining (NHEJ) or
single-strand annealing (SSA). The use of error-prone
mechanisms for DSB repair can result in genetic
changes involving rearrangements and sequence modifi-
cation at the damaged sites [3]. In this relation, it has
been shown that chromosomal instability arises after
inactivation of murine Brca2 gene, which is in agree-
ment with complex chromosomal changes observed in
human breast tumors derived from BRCA2 carriers
[4,5]. Consistent with Knudson’s two-hit hypothesis for
tumor suppression, loss of the wild-type (wt) BRCA2
allele has been described as an essential event in tumor
initiation in BRCA2 carriers [6]. This notion has,
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however, recently been questioned with data demon-
strating that loss of Brca2 heterozygosity is not a
required event in murine models of familial pancreatic
cancer and, for human carriers of the BRCA2 999del5
mutation, that loss of heterozygosity (LOH) might not
be needed to promote carcinogenesis in the pancreas
[7]. In addition, breast cancers arising in BRCA1 and
BRCA2 mutation carriers are heterogenic for LOH, sug-
gesting haploinsufficient effects in pathogenesis [8].
Genome-wide expression analyses of breast cancers
have led to the identification of biologically and clini-
cally relevant subtypes (that is, luminal-A (LumA),
luminal-B (LumB), basal-like, HER2, and normal-like)
[9]. The identified subtypes have shown substantial dif-
ferences with respect to copy-number changes, sug-
gesting that their development adheres to changes in
distinct sets of genes, leading to diverging tumor-evo-
lution pathways [10,11]. Of these, the luminal subtypes
comprise the majority of all cases (60% to 70%), both
characterized by expression of GATA3-regulated
genes. The LumB subtype differs from LumA by high
expression of proliferation-associated genes with
increased levels of MKI67 (Ki-67) as a prominent fea-
ture, and are associated with less-favorable disease out-
come [12]. Basal-like breast cancers are characterized
by expression of genes that pertain to the basal layer
of cells in normal mammary glands, such as CK5/6
and CK14. The basal-like and HER2 subtypes are both
highly proliferative, poorly differentiated, and, in con-
cordance, show the least-favorable disease outcome
[13]. Tumors arising in BRCA2 germline mutation car-
riers mostly display luminal phenotypes of high histo-
logic grade and have prominent expression of
proliferation markers, suggesting similarities to the
LumB subtype [14]. Relatively few BRCA2 tumors have
been profiled for copy-number changes, and have
mostly been studied by using low-resolution array
design, resulting in relatively crude patterns and lack
of clarity in identification of key drivers. In our pre-
vious report, we found that BRCA2 tumors often show
highly complex genomes coupled with a unique pat-
tern of copy-number changes [15]. To follow up on
these results, we have studied copy-number changes in
a larger number of BRCA2 tumors by high-resolution
array-comparative hybridization (aCGH) microarrays
containing 385 thousand probes (about one for each 7
kbp) in breast tumors derived from BRCA2 germline
mutation carriers (n = 33) combined with analysis of
phenotypic markers by immunohistochemistry (IHC)
on tissue microarrays (TMAs). The purpose of the
study was to characterize the spectrum of copy-num-
ber changes in tumors obtained from BRCA2 carriers
with respect to phenotype and clinical parameters.
Materials and methods
Study group
Tumor DNA samples (n = 33) were derived from
patients carrying the 999del5 BRCA2 germline muta-
tion [16]. The tumors were macroscopically examined
by a pathologist to identify portions with invasive
tumor cells. DNA extraction was performed on freshly
frozen tumor portions by following protocols based on
standard procedures by using phenol-chloroform and
proteinase K. Clinical parameters, including TNM sta-
ging and histologic grade, were obtained from the
Department of Pathology, Landspitali University, and
are given in Additional File 1. Data on S phase and
ploidy, obtained with flow cytometry, were available
for 30 of the 33 breast tumors analyzed in this study.
Data on patient relapse, that is, events of recurrences
or metastases after diagnosis and treatment, were
obtained from Landspitali University Hospital. This
work was carried out according to permits from the
Icelandic Data Protection Commission (2006050307)
and Bioethics Committee (VSNb2006050001/03-16).
Informed consent was obtained from all patients.
Array-comparative genomic hybridization
Copy-number changes were studied with high-resolution
385 K oligonucleotide CGH microarrays (Roche Nimble-
Gen, Inc., Reykjavik, Iceland) containing 385 thousand
probes covering the human genome with about one
probe for each 7 kbp. DNA derived from tumor- and
normal blood samples from the same individual were
Cy3 and Cy5 labeled, respectively. Sample labeling and
hybridizations were carried out according to protocols
developed by the manufacturer (NimbleGen Arrays
User’s Guide-CGH Analysis; Roche NimbleGen, Inc.,
Reykjavik, Iceland). The aCGH data are available online
from ArrayExpress [17] under the accession number E-
TABM-1199.
Fine-tiling aCGH analysis was performed by using the
385 K oligonucleotide CGH microarrays covering chro-
mosome 6 with about one probe for each 400 bp
(Roche NimbleGen, Inc.), following the manufacturers
protocols for sample labeling and hybridization (Roche
NimbleGen).
Tissue microarrays and expression analysis by
immunohistochemistry
TMAs construction and their application in expression
analysis by immunohistochemistry (IHC) have been
described previously [15]. Tumors were assigned to
molecular subtypes by using the five-biomarker scheme
described in Cheang et al. [13] by expression of estrogen
receptor (ER), progesterone receptor (PR), human epi-
dermal growth factor receptor 2 (HER-2), epidermal
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growth factor receptor (EGFR), and cytokeratin 5/6
(CK5/6). Expression of ER and PR were scored positive
(IHC score ≥ 1+) when IHC staining was observed in
more than 1% of tumor cell nuclei. HER-2 positivity was
scored for strong membranous staining (IHC score 3+),
whereas EGFR was scored positive for any, weak or
strong, membranous staining (IHC score ≥ 1+). Expres-
sion of CK5/6 was defined as positive when cytoplasmic
and/or membranous staining was observed and other-
wise considered negative. Hormone-receptor-positive
tumors, those positive for either ER or PR, were
assigned to the luminal subtype. Tumors negative for
ER, PR, and HER-2 were categorized as triple-negative
phenotype (TNP), whereas ER- and PR-negative tumors
displaying HER-2 positivity (IHC 3+) were assigned to
the HER2 subtype. Basal-like phenotype was assigned to
triple-negative tumors displaying expression of either
EGFR or CK5/6. Estimates for the expression of Ki-67
(MKI67), cyclin-D1 (CCND1), and topoisomerase II
alpha (TOP2A) gene products represent counts for the
proportion of positive tumor cells, based on nuclear
expression, reported on a scale from 0.0 to 1.0 within
intervals of 0.05. Luminal tumors showing Ki-67 expres-
sion ≥ 0.14 were assigned to the luminal B subtype,
whereas the remaining part was considered luminal A
[12]. Expression of p16 (CDKN2A) and pRb (RB1) was
scored on a discontinuous scale based on counts for the
proportion of tumor cells showing nuclear expression
(that is, 0 (< 10%), 1+ (10% to 25%), 2+ (25% to 50%),
and 3+ (> 50%). The antibodies and dilutions used in
IHC expression analysis are listed in Additional File 2.
TaqMan BRCA2 allele-specific quantitative PCR
The proportion of BRCA2 wild-type (wt) alleles was
quantitatively measured relative to 999del5 BRCA2
mutated alleles in tumor DNA samples by quantitative
polymerase chain reaction (PCR) (7500 Realtime PCR
system; Applied Biosystems) with a TaqMan method by
using a single BRCA2-specific, minor groove-binding
probe (MGB-probe) 5’-end-labeled with FAM and a
nonfluorescent quencher (NFQ) at the 3’ end, a single
BRCA2-specific forward primer, and two allele-specific
reverse primers. Therefore, the PCR for wt and mutant
alleles was performed in separate wells. The qPCR assay
primers and TaqMan-MGB probe were as follows: For-
ward primer: 5’-CATGATGAAAGTCGTAAGAAA-3’,
Reverse primer (mut): 5’-CATGACTTGCAGCTTC
TCTTTGTG-3’, Reverse primer (wt): 5’-CATGACTTG-
CAGCTTCTCTTTGAT-3’, TaqMan-MGB probe: 5’-
TTTATCGCTTCTGTGACA-3’. Reactions were at a 12-
μl final volume per well, each containing: TaqMan-MGB
at 50 nM, forward and reverse primers at 0.5 nM each,
6 μl TaqMan Universal PCR Master Mix (Applied Bio-
systems, Pn. 4304437), and 0.25 μg of sample DNA,
with H2O to final volume. The PCR: Step(S)1: 50°C for
2 minutes, S2: 95°C for 10 minutes, S3: 95°C for 15 sec-
onds, S4: 60°C for 1 minute, with S3 and S4 were
repeated for 40 cycles. The BRCA2 wt- to mutant-allele
ratios were quantified by measuring differences in fluor-
escence intensity of FAM performed in duplicate, and
the Ct values (number of cycles to reach intensity
threshold) were averaged. Ct measures with standard
deviation higher than 0.5 (SD > 0.5) were rejected and
remeasured. The wild-type to mutant-allele ratios were
calculated to wt/allele frequencies by the following
equation:
Frequency of allele1 = 1/(2Ct + 1)
where ΔCt = (Ct of allele1 - Ct of allele2) [18].
Statistical analysis and data mining of aCGH data
Preprocessing and segmentation of the aCGH data were
carried out as described previously [15]. Normalized
log2 ratios were replaced with corresponding segment
means for each probe represented on the arrays to
derive a segmented profile for each tumor. These data
were used as input for SAMr (significance analysis of
microarrays for R) in two-class or quantitative analysis,
in which repeated permutations are used to address
multiple testing [19].
Genetic networks represent a set of associated copy-
number changes (links) between distinct regions (nodes)
of the genome. Here, the average of segmented aCGH
log2 ratios was computed for each of 811 cytobands
with the nucleotide cytoband-locations downloaded by
using the UCSC table browser [20]. The pair-wise cyto-
band-cytoband associations were then determined by
hypothesis testing for Spearman’s rho (Stats package in
R). The P values for each of these comparisons were
then adjusted for multiple testing by the Holm proce-
dure (Multitest package in Bioconductor for R). Links
were then established for associations with Padj < 0.001,
while also having minimum event frequency of 25%.
The associations, or “genetic links,” represent nonran-
dom patterns of co-occurring copy-number changes.
We then split the links into sets of inter- and intrachro-
mosomal links involving associations between distinct
chromosomes (inter), or associations between distinct
arms on the same chromosome (intra), respectively. The
resulting networks of co-occurring genetic changes were
visualized as undirected node-and-edge graphs by mak-
ing use of the Rgraphviz package in Bioconductor for R.
Results
Breast cancer subtypes in BRCA2 mutated tumors
Thirty-three female breast cancer patients carrying the
same 999del5 BRCA2 germline mutation constituted the
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study group analyzed with array CGH (comparative
genomic hybridization). The year of diagnosis was
between 1989 and 1999, with the mean age of 50 years
(standard deviation (SD) = 12.2) (Additional File 1). Of
the 33 tumors analyzed with aCGH, 32 were available
on tissue microarrays (TMAs). Expression analysis of
subtype-specific biomarkers, that is, ER, PR, HER-2, Ki-
67, CK5/6, and EGFR, was performed on TMAs with
IHC. The results show that most BRCA2 tumors express
luminal markers (24 of 32; 75.0%), of which the majority
subcategorize as luminal B (16 of 24; 67%) rather than
luminal A (eight of 24; 33.3%) (Table 1). Notably, none
of the 32 BRCA2 tumors displayed overexpression or
high-level amplification of the human epidermal growth
factor receptor 2 (HER2) oncogene (Table 1). Of the
eight hormone-receptor negative BRCA2 tumors, all but
one was subcategorized as basal-like (seven of eight,
87.5%), of which four displayed EGFR expression, and
five were positive for CK5/6 (Table 1).
MKI67 (Ki-67) gene products tightly associate with
cellular proliferation and are often used to estimate
tumor growth rates [21]. Counting the number of tumor
cells positive for Ki-67 against the total number of
tumor cells reveals generally higher proliferation rates
Table 1 Phenotypic characterization of breast tumors derived from BRCA2 germline mutation carriers
Biomarkers for definition of phenotypes 0 I-II III
ER 8 (25%) 7 (22%) 17 (53%)
PR 12 (37%) 14 (44%) 6 (19%)
HER2 22 (69%) 10 (31%) 0 (0)
Cellular proliferation; The proportion of cells positive for Ki-67
Ki-67 0-14% (1st Qu.) > 14%-35% (IQR) > 35% (3rd Qu.)
Luminal 8 (33%) 14 (58%) 2 (8%)
Triple-negative 0 (0) 3 (37%) 5 (63%)
Χ2 test; P = 0.004
Expression of basal features
EGFR 0 I ≥ II
Luminal 22 (96%) 1 (4%) 0 (0)
Triple-negative 4 (50%) 1 (13%) 3 (37%)
Χ2 test; P = 0.004
CK5/6 Negative Positive
Luminal 24 (100%) 0
Triple-negative 3 (37%) 5 (63%)
Χ2 test; P = 0.0003
pRb/p16 pathway
p16 (CDKN2A) 0 I-II III
Luminal A 3 (38%) 4 (50%) 1 (12%)
Luminal B 9 (60%) 5 (33%) 1 (7%)
Triple-negative 0 1 (12%) 7 (88%)
Χ2 test; P = 0.0007
Cyclin-D1 (CCND1) 0-15% (1st Qu.) > 15%-75% (IQR) > 75% (3rd Qu.)
Luminal A 1 (12%) 4 (50%) 3 (38%)
Luminal B 1 (6%) 8 (50%) 7 (44%)
Triple-negative 6 (75%) 2 (25%) 0
Χ2 test; P = 0.005
pRb (RB1) 0 (Negative) I (Positive)
Luminal A 1 (13%) 7 (87%)
Luminal B 2 (13%) 14 (87%)
Triple-negative 4 (50%) 4 (50%)
Χ2 test; P = 0.085
Morphologic features
Histologic grade I II III
Luminal 2 (8%) 11 (44%) 12 (48%)
Triple-negative 1 (12%) 1 (12%) 6 (75%)
Χ2 test, P = 0.27
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among triple-negative BRCA2 tumors compared with
luminal BRCA2 tumors (c2 test; P = 0.004; Table 1;
Additional File 3). These differences coincide with high
p16 (CDKN2A) (c2 test; P = 0.0007), and low pRb (RB1)
in the triple-negative subtype of BRCA2 mutated breast
tumors (c2 test; P = 0.085) (Table 1). Increased p16
expression levels were highly correlated with decreased
pRb levels (Spearman correlation rho = -0.63; P =
0.0001). Accordingly, low pRb levels coupled with high
p16, that is pRblow/p16high, was commonly found in tri-
ple-negative BRCA2 tumors (four of eight; 50%), but
rarely in luminal BRCA2 tumors (two of 23; 8.7%) (c2
test; P = 0.043) (Additional File 3). In contrast, the lumi-
nal subtypes of BRCA2 mutated breast tumors were
associated with high expression of cyclin-D1 gene pro-
ducts (c2; P = 0.005) (Table 1).
DNA copy-number changes with respect to phenotype in
BRCA2-associated tumors
Event-frequency plots for copy-number changes in
BRCA2 tumors displaying luminal A, luminal B, and
basal/TNP describe the fraction of tumors within each
class, showing gains or losses in order of genomic posi-
tion (Figure 1a-c). Clearly, certain events occur more
Figure 1 Event-frequency plots for copy-number alterations and comparison between phenotypic subgroups of BRCA2 tumors. (a) The
proportion of gains (positive, dark blue) and deletions (negative, light blue) plotted on y-axis for each genomic location ordered from p- to q-
arm on x-axis left to right in BRCA2 tumors displaying luminal A (n = 8), and (b) luminal B (n = 16), and (c) basal/TNP phenotypes (n = 8). (d)
Comparison in copy-number alterations with significance levels (d) shown on y-axis and differences below a false-discovery rate of 0.05
indicated in red (cytoband locations) derived from comparisons between BRCA2 tumors displaying luminal A and luminal B phenotypes, (e)
between BRCA2 tumors displaying luminal A and basal/TNP, and (f) between BRCA2 tumors displaying luminal B and basal/TNP.
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frequently in the luminal types of BRCA2 tumors com-
pared with those of basal/TNP phenotypes and vice
versa. An important observation in this respect is that
some changes are inversely altered between the two
phenotypic subgroups (that is, luminal and TNP/basal).
To illustrate this point, it can be seen that changes over
12 q predominantly occur as gains in the luminal sub-
types, whereas they mostly occur as deletions in the
basal/TNP subtypes (Figure 1a-c). Detailed comparison
between each phenotypic subclass of BRCA2 tumors
shows that luminal A and B do not differ (Figure 1d).
However, substantial differences were revealed between
either luminal A or B when compared with TNP/basal
types of BRCA2 tumors (Figure 1e, f). Some of these dif-
ferences probably reflect phenotype-related effects inde-
pendent of BRCA2 abnormalities (for example, the
events at 5 q and 8 q have been described with respect
to phenotype in sporadic tumors elsewhere [10,22]).
However, other differences may relate to BRCA2 defects;
for example, deletions at 13q13.1, covering the BRCA2
gene locus, were highly prominent in BRCA2 tumors of
luminal B types compared with those displaying basal/
TNP features (Figure 1f).
Given the importance of the BRCA2 locus in this
study, we specifically explored the segmented aCGH
log2 ratios covering the BRCA2 gene along with analysis
of allele-specific BRCA2 loss with qPCR analysis. These
methods showed strong concordance (that is, changes in
aCGH log2 ratios at the BRCA2 locus significantly corre-
late with estimates of BRCA2 wild-type allele propor-
tions by qPCR; Pearson correlation r = 0.69; P =
0.000025). Looking separately at each of the two BRCA2
phenotypic subgroups (luminal and basal/TNP), a clear
trend toward deletion at the BRCA2 locus emerged for
the luminal types of BRCA2 tumors, in particular, in the
more-proliferative luminal B type (Figure 2a). Two indi-
vidual cancer genomes analyzed by aCGH are shown to
illustrate lack of deletion events affecting the BRCA2
Figure 2 The effects of BRCA2 deletion in phenotypic context. (a) Deletion at the BRCA2 locus measured by segmented aCGH log2 ratios
(left) and TaqMan qPCR (right) in relation to phenotype. (b) Example profiles derived from two BRCA2 tumors (a19861102, a128049) of the triple-
negative subtype analyzed by using 385 K aCGH (about one probe for each 7 kb). DNA gains or deletions are represented on the y-axis as black
bars toward positive or negative values, respectively, in order of the chromosomal location from p- to q-arm (left to right). Focused views of
chromosome 13 are displayed below each of the two profiles showing log2 ratios (gray dots) on y-axis by nucleotide position on x-axis from p-
arm to q-arm (left to right) with cytobands and the BRCA2 gene locus at 13q13.1 indicated as shown at the bottom of each plot. (c) S phase, (d)
Ki-67, and (e) Topo IIa in relation to changes at the BRCA2 gene locus, affecting the wild-type allele, in luminal- (left panel, gray circles) and
triple-negative phenotypes (right panel, black triangles).
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gene locus at 13q13.1 in the TNP subtype of BRCA2
tumors (Figure 2b). To examine this further, we studied
the relation on a continuous scale with markers of cellu-
lar proliferation that are S phase by flow cytometry,
along with expression of proliferation-associated genes
measured on a semicontinuous scale that is, Ki-67, and
Topo IIa. Estimates for S-phase fractions, indicative of
cells undergoing DNA replication, were found to be
associated with decreased proportions of BRCA2 wild-
type alleles in BRCA2 tumors of the luminal phenotype
(Pearson correlation, r = -0.56; P = 0.036) (Figure 2c).
This relation was not found in BRCA2 tumors display-
ing basal/TNP features, wherein very high proliferation
rates are attained independent of deletion events over
the BRCA2 locus at 13q13.1. Expression of Ki-67, as a
measure of cellular proliferation, has the benefit of
enabling stromal cells to be ignored, which is more diffi-
cult in analysis of S phase with flow cytometry. Esti-
mates for the proportion of Ki-67-positive tumors cells
were found to be correlated with decreased proportions
of wild-type BRCA2 alleles in BRCA2 tumors displaying
luminal characteristics (Pearson correlation, r = -0.59; P
= 0.0047), whereas the same was not found in BRCA2
tumors displaying basal/TNP phenotype (Pearson corre-
lation, r = 0.13, P = 0.76) (Figure 2d). In support for the
preceding, the same associations, with respect to BRCA2
wild-type allele loss and phenotype, were identified for
estimates of the cell-cycle associated gene product Topo
IIa (Figure 2e).
Genetic networks
DNA copy-number changes showing significant associa-
tions between distinct chromosomal regions in the set
of 33 BRCA2 tumors were identified, and visualized as
an undirected node-and-edge graph in which significant
correlations are represented as edges, with genomic
regions as nodes (Figure 3a, b; Additional File 4). This
analysis identified a set of 14 cytobands involving three
distinct interchromosomal links in association with the
BRCA2 locus at 13q13.1, that is, deletions at 6q22.32-
q22.33 and 11q14.2-q24.1, along with copy-number
gains at 17q24.1 (Figure 3b, Additional File 4). It is
important to note here that the data on BRCA2wt-speci-
fic loss confirmed the links identified with respect to
6q22.32-q22.33 and 11q14.2-q24.1 (Additional File 5).
Based on the BRCA2-linked networking regions
(6q22.32-q22.33, 11q14.2-q24.1, 13q13.1, and 17q24.1),
two subgroups were identified through cluster analysis
(Figure 3c). Evidently, these subgroups differ by the
degree of change over the regions identified in associa-
tion with the BRCA2 gene locus. Here, measures of
higher clinical staging at the time of diagnosis, involving
metastasis to the lymph nodes, were more prominent in
the subgroup showing changes over the BRCA2-linked
networking regions (Figure 3c). Data on patient relapse
were available in some of these cases, defined as an
instance of subsequent metastasis or recurrence, which
provided support for the hypothesis generated here that
DNA copy-number changes over the BRCA2-linked net-
working regions promote progression toward more-
advanced forms of the disease (see Figure 3c). In all
cases, metastasis to more-distant sites of the body was
involved, of which all but one occurred as bone metas-
tases. To determine whether the network of genetic
changes identified in relation to the BRCA2 locus at
13q13.1 is specific for BRCA2 mutated breast cancers,
we looked at our previously published data on sporadic
breast cancers [15]. As expected, the BRCA2 locus at
13q13.1 was not represented within the genetic net-
works constructed by using the same approach for
sporadic breast cancers (Additional File 4).
In a two-class comparison for BRCA2 tumors with or
without evidence of metastasis to the lymph nodes, or
other more distant sites, loss over the BRCA2 locus at
13q13.1 was identified in this analysis as significantly
associated with metastasis to the lymph nodes, along
with the BRCA2-linked networking regions at 6 q and
11 q (Figure 4). Of these, deletions at chromosome 6 q
were the most predictive for lymph node positivity, or
“metastatic capacity,” with the strongest associations
(significance peaks) found at 6q16.3 and 6q22.33. Look-
ing at the frequency of copy-number changes at
6q22.33, we identified a shift toward increased frequency
of deletions at a location close to the PTPRK gene,
which affected four other genes, that is EEF1DP5,
LAMA2, ARHGAP18, and C6orf191 (Additional File 6).
Fine-tiling aCGH analysis at exon-level resolution
(about one probe for each 400 bp) covering chromo-
some 6 confirmed deletions at 6q22.33 (Additional File
7). This analysis shows that the events at 6q-arm occur
as complex deletions confined within the 6 q chromoso-
mal region. Here, one of the tumors had acquired a
breakpoint event located within the 6q22.33 cytoband
proximal to the PTPRK gene affecting upstream regions
(Additional File 7). This subregion within the 6q22.33
cytoband was not affected in the lymph-node-negative
tumor, but rather involved a region downstream of the
PTPRK gene (Additional File 7).
The analysis of ploidy in BRCA2 mutated breast cancers
with respect to DNA copy-number changes by aCGH
Data available on ploidy were analyzed with respect to
DNA copy-number changes to follow-up on recent
results demonstrating poor disease outcome for BRCA2
carriers diagnosed with breast tumors of the diploid
type (Tryggvadottir et al., 2011; unpublished data). In
line with the less-favorable prognosis associated with the
diploid type of BRCA2 tumors, we found that BRCA2
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mutated tumors, having acquired changes over the
BRCA2-networking regions, were often identified as
diploid with flow cytometry (Figure 3c).
To study this further, we compared event-frequency
plots and the altered genome fractions for BRCA2
tumors of the diploid and aneuploid types. This analysis
shows that the amounts of genomic changes are not
fewer in diploids (Figure 5a) and, although not statisti-
cally significant, that the regions affected more fre-
quently by DNA copy-number changes in the diploid
types overlap with those referred to here as the BRCA2-
networking regions (Figure 5b). It is clear that the gen-
omes of BRCA2 mutated breast cancers classified as
diploid are extensively altered, and individual examples
are presented here to demonstrate complex patterns of
genomic changes (Figure 5c).
Discussion
In this study, we show that breast tumors from BRCA2
999del5 mutation carriers, displaying luminal- or basal/
triple-negative phenotypes (TNPs), differ with respect to
patterns of copy-number changes and markers of pRb/
Figure 3 Genetic networks in BRCA2 tumors. (a) Matrix of associations with blue and red reflecting P values (Holm adjustment for multiple
testing) for distinct chromosomal regions where copy-number changes co-occur in patterns of loss-loss or gain-gain relations, represented in
blue, or gain-loss relations represented in red. (b) Genetic networks; interchromosomal links constructed for relations below Holm-adjusted P
values of 0.001 (edges) between distinct genomic regions (nodes), with deletions in red and gains in blue, showing multiple links adjacent to
the BRCA2 locus at 13q13.1 (box). (c) Hierarchic cluster analysis of copy-number changes, deletions in red and gains in blue, over the subnet of
chromosomal regions linked to 13q13.1 (BRCA2) in relation to the occurrence of lymph node metastasis at diagnosis, and later relapse involving
distant metastases represented in colors of green (positive) or black (negative), ploidy as green for diploid and black for aneuploid (see color
codes at bottom of heatmap), along with TNM stage.
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Figure 4 Two-class comparative analysis displaying event-frequency plots for BRCA2 tumors with (blue) and without (red) evidence
for lymph node metastases at diagnosis. The fraction of tumors with acquired changes are represented on the y-axis with positive values for
gains, and negative for deletions, ordered by chromosomal location on x-axis from p- to q-arm, from left to right. The significance scores (d),
derived from a permutation-based procedure (SAM two-class unpaired), representing the strength of association, are shown in the lower panel
with relations below a false-discovery rate of 0.05 indicated in red (cytoband locations).
Figure 5 The effects of ploidy on DNA copy-number changes in BRCA2 breast tumors. (a) Event-frequency plots to compare the genomic
regions affected in diploid (blue) and aneuploid (red) types of BRCA2 tumors. (b) The proportion of the genome altered in BRCA2 tumors with
respect to ploidy. (c) Three example genomic profiles analyzed by aCGH to illustrate complex changes in BRCA2 tumors classified as diploid by
flow-cytometry. The genomic profiles represent DNA copy-changes number toward gains (above) or losses (below) on the y-axis by
chromosomal position on the x-axis from p- to q-arms, left to right, respectively.
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p16 pathway dysfunction, suggesting divergent paths of
tumor evolution. This finding led to important observa-
tions regarding loss of the wild-type (wt) BRCA2 allele
in luminal types of BRCA2 tumors, where it associates
with increased tumor growth rates. Furthermore, we
find that deletion of the BRCA2wt allele represents a
part of a larger network of co-occurring genetic changes
that relate to advanced progression, involving deletions
at 6q22.32-q22.33, 11q14.2-q24.1, as well as gains at
17q24.1. These results suggest that loss of the BRCA2wt
allele is not required in tumor initiation, but rather
plays an important role later in disease progression.
Recently, it was demonstrated that heterozygosity for
Brca2 is sufficient to promote carcinogenesis in a mur-
ine model of familial pancreatic cancer and also that
LOH might not be essential for human pancreatic ductal
carcinogenesis in BRCA2 999del5 mutation carriers [7].
In addition, an earlier study on breast cancer samples
from carriers of different BRCA2 mutations showed
retention of the BRCA2wt allele in some cases, provid-
ing support for our conclusion [8]. We conclude that
loss of the BRCA2wt allele, although not required in
tumor initiation, is not a randomly occurring passenger
but rather an important driver event in leading to selec-
tive growth advantages and higher clinical staging of the
disease. These effects are likely indirect, resulting from
accelerated mutation rates, from which advantageous
mutations can arise and lead to a more aggressive
phenotype.
The majority of the BRCA2-associated tumors under
study displayed luminal characteristics, whereas the
remaining part was of basal/triple-negative phenotype
(TNP). Notably, none of the BRCA2 tumors showed
overexpression or high-level amplification of the HER-2
oncogene. This subdivision of BRCA2 tumors into phe-
notypic subgroups is in agreement with our previous
study and those of others [14,15]. The loss of pRb
observed in the basal/TNP subtype of BRCA2 mutated
breast tumors likely reflects acquired defects in the RB1
gene. Indeed, high expression of CDKN2A (p16) gene
products, indicative of functional defects in RB1, has
been described as a defining feature of basal-like breast
cancers, and it has been suggested that this may repre-
sent an important early event in bypassing cellular stress
and replicative senescence [23,24]. The negative-feed-
back loop between high p16 and low pRb has been
described and is known to be the result of pRb binding
to the CDKN2A (p16) gene promoter, leading to tran-
scriptional repression of CDKN2A [25]. Increased
expression of CDKN2A (p16) gene products arises
under normal circumstances as a response to stress sig-
nals, such as telomere crisis or DNA damage. Thus,
unimpeded cellular proliferation, indicated by expression
of cell-cycle markers such as Ki-67, in combination with
the presence of high p16 expression levels, could be
indicative of abrogated p16/RB checkpoint control [23].
We found high expression of MKI67 (Ki-67) gene pro-
ducts, a marker for cellular proliferation, in basal/TNP
BRCA2 tumors, together with low pRb and high p16
levels. In contrast, the luminal subgroup of BRCA2
tumors rarely showed high p16 expression levels and
almost invariably showed pRb expression. Given the
association for loss of BRCA2wt alleles with respect to
the luminal phenotype, this finding would have been
unexpected as the RB1 (pRb) gene resides close to
BRCA2 on chromosome 13q. Nevertheless, the associa-
tion of p16/pRb dysfunction to the basal/TNP subtype,
identified here in BRCA2 mutated breast tumors, is
similar to that reported in sporadic tumors suggesting
that the events leading to the basal/TNP phenotype in
carriers and noncarriers could be the same. In this
respect, it has been demonstrated that BRCA1 inactiva-
tion in sporadic disease leads to development of basal/
TNP breast cancers [26,27]. In our recent report, we
described the loss of pRb, coupled with high p16, in
BRCA1-defective breast cancers [27]. We therefore pos-
tulate that the event of acquired defects in the BRCA1
gene could have the same effect in BRCA2 mutation
carriers, as seen in sporadic breast cancers. Presumably,
this would alleviate selection pressure for loss of the
BRCA2wt allele in BRCA2 mutation carriers. This is
consistent with the data presented here, demonstrating
lack of definitive BRCA2wt loss in the basal/TNP sub-
class of BRCA2 tumors.
Whole-genome copy-number changes in this same set
of BRCA2 tumors analyzed with high-resolution (~7
kbp) aCGH demonstrated substantial differences
between luminal- and basal/TNP subtypes of BRCA2
tumors. These differences involved frequent alterations
at multiple chromosome locations in luminal BRCA2
tumors that were infrequently or inversely altered in
basal/TNP BRCA2 tumors. Their unique patterns of
copy-number changes suggest that the two phenotypic
subclasses of BRCA2 tumors develop in different ways.
Of particular interest here are the luminal subtypes of
BRCA2 tumors showing more-frequent deletions over
the BRCA2 gene locus. Here, gradual decreases in the
proportion of BRCA2wt alleles present within the tumor
mass were correlated with increased growth rates, sug-
gesting selective advantages for the event of BRCA2wt
loss. It can be hypothesized that this relation reflects a
progression pattern involving clonal expansion of tumor
cells that have acquired deletion of the BRCA2wt allele.
This appears contradictory to previous studies demon-
strating that targeted disruption of the Brca2 gene nega-
tively affects cell-cycle progression [28]. Other changes
could therefore be required to overcome the deleterious
effects of BRCA2 deficiency. In this respect, the network
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of genetic changes affecting 6q22.32-q22.33, 11q14.2-
q24.1, and 17q24.1 identified in association with
BRCA2wt loss could be of critical importance in pro-
moting survival of BRCA2-defective tumor cells. This
would give rise to cancer cells with BRCA2 deficiency,
thereby leading to accelerated mutation rates and,
through the forces of natural selection, advantageous
changes could accumulate and eventually lead to disease
progression. Indeed, we find that the set of co-occurring
changes linked to the BRCA2 region at 13q.13.1 coin-
cide with those that associate with advanced disease
progression involving metastasis to the nodes, and
patient relapse involving distant metastases. Here, dele-
tion events at chromosome 6 q were the strongest pre-
dictors of metastatic capacity. To gain further insight
into the genetic events occurring at this location, we
performed fine-tiling aCGH analysis (exon-level resolu-
tion). Detailed views of changes at 6q22.33 (that is, the
highest ranking of the BRCA2-linked genomic regions)
suggested the involvement of genes located at, or down-
stream, of a breakpoint event disrupting protein tyrosine
phosphatase, receptor type, K (PTPRK), a putative
tumor suppressor gene known to be involved in TGF-b
signaling [29]. Interestingly, the 6q22.33 region has been
identified as a breast cancer susceptibility locus where
two candidate genes are located, that is, RING finger
protein 146 (RNF146) and enoyl coenzyme A hydratase
domain-containing 1 (ECHDC1) [30]. Looking at break-
point events at chromosome 6 q by using the fine-tiling
aCGH analysis, we did not find strong evidence for
gross genetic changes indicative of error-prone DNA
repair through NHEJ, similar to that reported for the
PTEN gene at chromosome 10 q in BRCA1 mutated
breast tumors [31]. However, it is clear that, in most
cases, these events involve complex changes as they are
not characterized by loss of the entire 6 q arm. Dele-
tions at 11 q have been described previously in associa-
tion with BRCA2 breast tumors wherein aberrant
expression of ATM has been demonstrated [32]. How-
ever, the region at 11q14.2-q22.2, including MRE11, has
not been studied previously in this respect. The subnet
of genetic links associated with the BRCA2 gene locus
warrants further investigation in terms of which genes
are involved and whether they explain disease outcome
in BRCA2 carriers and other patients with or without a
family history of the disease. This could be of potential
significance in defining a set of biomarkers for use in
clinical settings to identify HR defects (that is, markers
of BRCAness) [33].
In looking at data from flow-cytometry, we observed
diploidy as a common feature of those BRCA2 tumors
displaying changes over the BRCA2-linked regions.
Clearly, this was unexpected, as diploid tumors are
usually associated with genomes characterized by few or
no genomic changes (that is, simple genomes) [34]. This
finding has relevance to a recent study on survival in
BRCA2 mutation carriers, wherein tumors classified as
diploid were found to be associated with fast disease pro-
gression independent of hormone receptors, histologic
grade, and TNM stage (Tryggvadottir et al., 2011, unpub-
lished data). Here, we add important insight into this,
with data demonstrating complex genetic changes in gen-
omes of BRCA2 tumors identified as diploid with flow-
cytometry. The presence of genomic complexity in
BRCA2 tumors of the diploid class demonstrates that
they are pseudo-diploids. Nevertheless, the differences in
disease outcome with respect to ploidy in BRCA2 carriers
are compelling and suggestive of divergent tumor-pro-
gression paths. In this respect, it has been shown that
approximately 30% of all breast tumors classified as
diploid by flow-cytometry have acquired complex pat-
terns of genetic changes, as identified through aCGH-
based method (ROMA) [34]. Importantly, the two differ-
ent instability-types described (that is, firestorm and saw-
tooth), were associated with poor disease outcome. Thus,
it seems likely that at least a certain proportion of tumors
classified as diploid by conventional flow-cytometry
could be promoted by acquired defects in components of
the HR machinery, possibly involving the BRCA2 gene.
Inhibitors of PARP1 gene products have been shown
to kill BRCA1- or BRCA2-defective cells selectively, with
no effects on heterozygous cells, and such inhibitors are
currently being tested in clinical trials [35]. Our results
could have clinical implications regarding the use of
PARP inhibitors, with observations demonstrating late
involvement for loss of the BRCA2wt allele. In this
respect, PARP inhibitors will probably not be sufficient
alone (that is, as monotherapy), for treatment of BRCA2
carriers. Nevertheless, the risk of progression toward
advanced disease in the event of BRCA2wt allele loss is
of considerable concern, and our results therefore
strongly support adjuvant use of PARP inhibitors in
standard treatment of all BRCA2 mutation carriers.
Conclusions
In conclusion, our results demonstrate phenotypic het-
erogeneity of breast cancers arising in carriers of the
same 999del5 BRCA2 mutation. We show that the lumi-
nal- and basal/TN phenotypes develop through diver-
gent tumor evolutionary paths. Here, loss of the BRCA2
wild-type allele occurs more frequently in the luminal
subtype, where it correlates with increased tumor
growth rates. Furthermore, the event of BRCA2wt allele
loss occurs in the context of other genetic changes,
involving deletions at 6 q, 11 q, and copy-number gains
at 17 q. These changes, including deletions over the
BRCA2 gene locus, were found to be associated with
higher clinical staging at diagnosis involving metastasis
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to the lymph nodes, and correlated with patient relapse.
These observations could explain why BRCA2 carriers
have predilection for developing breast cancers of the
luminal B phenotype. The findings presented here, sug-
gesting that loss of the BRCA2wt allele is a late, rather
than early, event in progression toward metastatic dis-
ease, have clinical relevance supporting adjuvant, and
not single-agent, use of PARP inhibitors in treatment of
BRCA2 carriers.
Additional material
Additional file 1: Phenotype and clinical parameters. Table listing
tumor phenotype and clinical parameters including breast cancer
subtype, histologic grade, and TNM stage.
Additional file 2: Antibodies for expression analysis on TMAs. Table
listing the antibodies used for immunohistochemistry on tissue
microarrays (TMAs).
Additional file 3: The expression of Ki-67, p16, and pRb in BRCA2
mutated breast cancers by phenotype. Expression of Ki-67, p16, and
pRb by IHC on tissue microarrays (TMAs) in subtypes of BRCA2 breast
tumors. (a) The distribution of Ki-67 expression levels, reflecting cellular
proliferation, compared between BRCA2 tumors of basal/triple-negative
and luminal phenotypes. Example IHC analysis for Ki-67 shows higher
proportion of positive cells in BRCA2 tumors of triple-negative (lower
panel) compared with luminal phenotypes (upper panel). (b) Expression
of p16 (CDKN2A) in BRCA2 tumors by phenotype with low expression of
pRb (IHC null) indicated, see Table 1 for details. Examples show
representative BRCA2 tumors of luminal- (upper panel) and triple-
negative (lower panel) phenotypes.
Additional file 4: The complete set of links identified in breast
cancers graphically represented as node-and-edge graphs, shown
here separately for those derived from BRCA2 carriers and sporadic
cases. Genetic networks constructed for relations below Holm-adjusted P
values of 0.001 (edges) between distinct genomic regions (nodes), with
deletions in red and gains in blue. The links identified, reflecting co-
occurring genetic changes, were split into sets of inter- and
intrachromosomal links characterized as those involving distinct
chromosomes (inter, left on figure) or distinct arms on the same
chromosome (intra, right on figure), respectively. (a) The genetic
networks constructed for BRCA2 mutated breast cancers, and (b) those
arising in the sporadic setting.
Additional file 5: BRCA2 wild-type allele specific qPCR examined
with respect to DNA copy-number changes. Deletion of wild-type
BRCA2 alleles by TaqMan qPCR analysis were examined on a continuous
scale in relation with the genome-wide segmented aCGH log2 ratios by
using a regression model with repeated permutations to address the
problem of multiple testing, as implemented in SAM (quantitative
analysis). The significance scores (r) derived from this analysis are plotted
on the y-axis for each genomic location ordered from p- to q-arm on
the x-axis, from left to right, with relations below a false-discovery rate of
0.0001 indicated by red dots.
Additional file 6: Detailed analysis of event frequencies at
chromosome 6 q in BRCA2 mutated breast cancers. Analysis of DNA
copy-number changes occurring at chromosome 6 in BRCA2 tumors. (a)
Top: Comparison for the frequency of events in BRCA2 tumors with and
without evidence for metastatic spread to the lymph nodes or other
sites at diagnosis, a trait reflecting metastatic capacity, represented in red
and orange, respectively (see legend at the top right corner). Bottom:
Zooming in on the frequency of events at 6q22.33, selected for further
analysis, as this region strongly associates with metastatic capacity in
BRCA2 tumors while also being linked to deletions over the BRCA2 gene
locus at 13q13.1. (b) Top: Example of fine-tiling aCGH analysis (exon-level
resolution) for chromosome 6 in one BRCA2 breast tumor where aCGH
log2 ratios are plotted on the y-axis in order of nucleotide position on
the x-axis. Dashed vertical lines represent locations of cytoband
boundaries, as indicated below, and solid horizontal red lines represent
output derived from CBS analysis for detecting copy-number changes
with negative values of segmented aCGH log2 ratios reflecting change
toward deletions, and positive values as change toward copy-number
gains. Bottom: Enlarged, detailed view of the entire 6q22.33 region in
this tumor shows a breakpoint event occurring nearby the PTPRK gene, a
frequent site of deletion events in metastatic BRCA2 tumors (see data in
Figure 5a, bottom panel) affecting four other genes within this cytoband
(EEF1DP5, LAMA2, ARHGAP18, and C6orf191).
Additional file 7: aCGH analysis using fine-tiling arrays (400 bp) for
chromosome 6 in BRCA2 mutated breast cancers. Fine-tiling aCGH
analysis (exon-level resolution) covering chromosome 6, with about one
probe for each 400 bp, was performed to reanalyze and confirm events
at this chromosome with greater clarity in three of the BRCA2 tumors.
The aCGH log2 ratios are plotted on the y-axis in order of nucleotide
position on the x-axis, with dashed vertical lines representing locations of
cytoband boundaries, as indicated below. Solid horizontal red lines
represent output derived from CBS analysis for detecting copy-number
changes with negative values of segmented aCGH log2 ratios reflecting
change toward deletions, and positive values as change toward copy-
number gains.
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